Biogen Inc vs Levi Strauss & Co. — how do they compare? Biogen Inc trades at $204 (market cap $30.13B), while Levi Strauss & Co. trades at $22.73 (market cap $8.75B). The key difference: Biogen Inc is far larger — about 3.4× Levi Strauss & Co.'s market cap, and Levi Strauss & Co. pays a 2.81% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BIIB | LEVI | |
|---|---|---|
Market Cap | $30.13B | $8.75B |
Sector | Health | Consumer Cyclical |
52-Week High | $216.63 | $25.53 |
52-Week Low | $128.93 | $17.92 |
Enterprise Value | $37.20B | $10.07B |
Dividend Yield | — | 2.81% |
Trailing returns across standard periods
Latest headlines on both assets
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →Levi Strauss & Co is involved in designing, marketing, and selling products that include jeans, casual and dresses pants, tops, shorts, skirts, jackets, footwear, and related accessories directly or through third parties and licensees for men, women, and children under Levi's, Dockers, Signature by Levi Strauss & Co. and Denizen brands. The company manages its business according to three regional segments: the Americas, which is the key revenue driver
Read more on LEVI →